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ABSTRACT
Background This study aims to compare information from hospital episode statistics (HES) and traditional direct patient contact to identify
readmission and clinical events in the follow-up of a randomized controlled trial (RCT).
Methods The study followed 1812 patients for 28 days using direct contact (DC). In addition, we obtained HES for this period. We examined
medical records for all suspected readmissions and determined conﬁrmed events by adjudication. We compared the ability of the individual DC
and HES methods to determine readmission and the occurrence of trial-speciﬁc events, conﬁrmed at adjudication.
Results In the ascertainment of readmission, compared to DC, HES demonstrated a trend towards better sensitivity (identifying 153/166 =
92.2% versus 144/166 = 86.7%; difference = 5.4%, 95% CI: 0.1–11.5%) and better speciﬁcity (1492/1492 = 100% versus 1426/1492 =
95.5%; difference = 4.4%, 95% CI: 4.2–5.6%).
An examination of HES coding does not identify rates for speciﬁc events that match those from adjudication, with limitations in both
sensitivity and speciﬁcity.
Conclusion HES is effective in the ascertainment of readmission and is a useful tool in follow-up. Information from HES provides a reﬂection of
a patient’s course and associated cost, as perceived by the healthcare system. Future studies could modify outcome deﬁnitions to reﬂect
episode coding.
Keywords cardiology intervention, hospital episode statistics, primary percutaneous coronary intervention, randomized controlled trials, trial
follow up
Introduction
Loss to follow-up can compromise the external and internal
validity of a trial. Traditional methods of follow-up are often
expensive and time-consuming, involving direct contact with
each study participant over a prolonged period. The use of
novel methods of trial follow-up, such as electronic data-
bases, may reduce the cost, avoid loss to follow-up and be
more convenient for research staff and patients. Hospital
episode statistics (HES) is a centralized database containing
information for all patient care delivered in England in NHS
facilities. HES is compiled from the coding data received
from NHS trusts. Each episode of care is identiﬁed from
the patients’ hospital notes and recorded as a series of diag-
nostic codes taken from International Classiﬁcation of
Diseases 10th Revision (ICD-10). Each code in HES is
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associated with a tariff that determines how much the hos-
pital is paid per admission.
The objective of this study was to use the data from
the HEAT-PPCI trial (How Effective are Antithrombotic
Therapies in Primary Percutaneous Coronary Intervention)
to compare ability of the individual DC and HES methods
to determine the incidence of conﬁrmed readmission.1 A
second objective was to compare the ability of HES data to
identify the occurrence of trial-speciﬁc events declared by
adjudication.
Methods
Patients and study design
HEAT-PPCI was a single-centre, randomized controlled trial
comparing unfractionated heparin versus bivalirudin in the
treatment of patients with suspected ST-elevation myocardial
infarction (STEMI). Recruitment took place from 7 February
2012 to 20 November 2013 and 1812 participants were
included in the HEAT-PPCI ﬁnal analysis. Participants were
tracked during their index admission for clinical events, by
careful review of case notes, and followed up for 28 days fol-
lowing randomization.
The primary objective of follow-up in HEAT-PPCI was to
establish vital status and the occurrence of any pre-speciﬁed
outcome measures. This involved identifying all overnight
admissions during the follow-up period and was achieved by
direct patient contact (DC) at 4–6 weeks following random-
ization. The method of contact used was recorded for all
patients (Fig. 1). In addition, HES reports were examined for
each patient to supplement the information obtained by DC.
Suspected readmission events identiﬁed by either DC or
HES data were then conﬁrmed by review of the medical
notes.
Method of assessing the accuracy of DC and HES in
identifying readmissions
Patients who had a HES report and responded to direct con-
tact were included in this analysis. The number of readmis-
sions determined by the individual DC and HES methods
were then compared to the total number of readmissions
conﬁrmed by the medical notes. When evaluating DC, if a
readmission was not identiﬁed by DC but was identiﬁed by
HES and subsequently conﬁrmed by medical notes review,
this was recorded as a false negative result. When evaluating
the HES data, if a readmission was identiﬁed in the HES
data but not conﬁrmed by medical notes review, this was
recorded as a false positive result. If a readmission was not
identiﬁed by HES but was identiﬁed by DC and subsequently
conﬁrmed by medical notes review, this was recorded as a
false negative result. From these data we could then calculate
the sensitivity, speciﬁcity, positive predictive value (PPV) and
negative predictive value (NPV) of each method.
Method of assessing the diagnostic accuracy of HES
data
The primary efﬁcacy outcome of the HEAT-PPCI trial was
the proportion of patients who had at least one major adverse
cardiovascular event (MACE) at 28 days. MACE included all-
cause mortality, cerebrovascular accident (CVA), reinfarction
or additional unplanned target lesion revascularisation. The
primary safety outcome was the proportion of patients who
had a major bleed by 28 days, classiﬁed as types 3–5 accord-
ing to the Bleeding Academic Research Consortium (BARC).1
Key clinical information from each patient was reviewed by a
blinded physician adjudication panel. This panel would then
establish if outcome events had occurred in terms of the spe-
ciﬁc event deﬁnitions declared in the trial protocol.
The HES data obtained for the 28 days following ran-
domization was examined to identify ICD-10 codes that
indicated the occurrence of any primary efﬁcacy or safety
outcome pre-speciﬁed in the HEAT-PPCI trial. All patients
who were randomized and for whom HES data were
obtained were included in this analysis. To identify key clin-
ical events, the relevant ICD-10 codes were used to search
the HES database (see Table 1 in online supplemental
material). The events identiﬁed in the HES data were com-
pared with those declared by physician adjudication. If a
diagnosis was identiﬁed in HES that was not identiﬁed by
physician adjudication, this was recorded as a false positive
result. If a diagnosis was not identiﬁed in HES but was iden-




The HEAT-PPCI trial included 1812 patients. Following ran-
domization, 73 patients died in hospital before they were dis-
charged from the index event and 39 participants remained
inpatients at 28 days. Of the remaining 1700 with the poten-
tial to be re-admitted during the 28-day follow-up period,
1644/1700 = 96.7% were successfully followed up by both
DC and HES (Fig. 1).
The full results of the analysis of readmissions are pre-
sented in Table 1. HES identiﬁed 153/166 of conﬁrmed
readmissions (Sensitivity: 153/166 = 92.2%; 95% CI:
87.1–95.4%). HES missed 13 conﬁrmed readmissions. All
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readmissions identiﬁed by HES were conﬁrmed readmis-
sions (speciﬁcity: 1492/1492 = 100%; 95% CI: 99.7–100).
During the follow-up period, 14 patients experienced 2 con-
ﬁrmed readmissions and 28/28 = 100% of these were iden-
tiﬁed in HES.
DC identiﬁed 144/166 conﬁrmed readmissions (Sensitivity:
144/166 = 86.7%; 95% CI: 80.7–91.1) and missed 22 con-
ﬁrmed readmissions. DC identiﬁed 66 suspected readmissions
that were not found to be conﬁrmed readmissions (speciﬁcity:
95.6%; 95% CI: 94.4–96.5). DC identiﬁed 16/28 readmis-
sions in patients found to have 2 conﬁrmed readmissions.
Identifying clinical events
Evaluable HES data were obtained for 1754 patients. Figure
2 describes the reasons why these data were not obtained
for other trial subjects. The full results for this analysis are
presented in Table 2.




Other direct patient contact (email, 
text message)
47 (2.9%)
GP or other primary care provider 48 (2.9%)
Outpatient clinic 44 (2.7%)
Inpatient 18 (1.1%)
Total 1644
1700 follow-up by direct contact and HES is attempted
1644 successfully followed up by both methods 
56 do not have BOTHHES and direct contact:
3 lost to direct contact 
52 lost to HES
1 lost to both direct contact and HES 
1812 included in HEAT-PPCI analysis
112 do not require follow-up:
73 died during index period
39 remained inpatients at 28 days
1426 have no readmission identified by 
either method
HES OR direct contact identifies 218 patients who have readmissions 
152 patients have readmissions that are confirmed by review of medical notes
66 patients have reported readmissions that 
are refuted by review of medical notes
138 patients confirmed to have a 
single readmission 
14 patients confirmed to 
have 2 readmissions
Fig. 1 Flow diagram outlining the follow up obtained by direct contact and HES methodology for identifying readmissions. HES = Hospital Episode Statistics.
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During the index admission, HES correctly identiﬁed
1/29 = 3.4% (95% CI: 0.6–17.2) of the recurrent MIs,
16/22 = 72.7% (95% CI: 51.8–86.8) CVAs and 143/222
= 64.6% (95% CI: 57.9–70.4) bleeding events. HES iden-
tiﬁed 15 recurrent MIs, 1 CVA and 175 bleeding events
that were not conﬁrmed by adjudication.
Following discharge, HES identiﬁed 2/3 = 66.7% (95%
CI: 20.8–93.9) of recurrent MIs, 4/5 = 80.0% (95% CI:
37.6–96.3) CVAs and 15/31 = 48.4% (95% CI: 31.9–65.2)
bleeding events. HES incorrectly identiﬁed 46 recurrent
MIs, 8 CVAs and 7 bleeding events that were not conﬁrmed
on adjudication.
Discussion
Main ﬁndings of this study
HES and DC are both effective methods of ascertaining
readmission in a clinical trial. Our results show that the most
comprehensive information was obtained when both meth-
ods were used together. Compared to DC, HES demon-
strated a trend towards better sensitivity and speciﬁcity. An
analysis of HES coding does not result in rates for speciﬁc
events that match those from adjudication, with limitations
in both sensitivity and speciﬁcity.
What is already known on this topic
A recent study showed that the use of HES data in research
has increased from 1 publication in 1996 to a total of 520 pub-
lications by 2014.2 This trend may be due to advantages in
using HES over more traditional methods of data collection.
For instance, HES captures all events, diagnoses and proce-
dures as perceived by the health service. It records what ‘the
system says has occurred’ during a hospital admission. This
information may better reﬂect the true societal impact, both
clinical and ﬁscal, of the outcomes of trial patients. A study
looking at the accuracy of using HES data to calculate inpatient




Sensitivity (CI) Speciﬁcity (CI) PPV (CI) NPV (CI)
Readmission No readmission
HES detects readmission 153 0
HES does not detect readmission 13 1492 92.2 (87.1–95.4) 100 (99.7–100) 100 (97.6–100) 99.1 (98.5–99.5)
Readmission No readmission
DC detects readmission 144 66
DC does not detect readmission 22 1426 86.7 (80.7–91.1) 95.6 (94.4–96.5) 68.6 (62.0–74.5) 98.5 (97.7–98.9)
HES = Hospital Episode Statistics; DC = direct contact; CI = 95% conﬁdence interval; PPV = positive predictive value; NPV = negative predictive value.
1754 had HES data available for analysis
1812 included in HEAT-PPCI analysis
58 patients had no evaluable HES data:
13 had no NHS number
43 were not found in HES database
2 had incorrect NHS numbers
64 patients have 
recurrent MIs 
identified in HES
333 patients have 
bleeding events
identified in HES
24 patients have 
CVAs identified in
HES
85 patients died, 
identified in NHS 
mortality database
Fig. 2 Flow diagram outlining the number of patients who were identiﬁed by HES as having a clinical event in the 28 days following randomization. HES =
Hospital Episode Statistics; MI = myocardial infarction; CVA = cerebrovascular accident.
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costs found that data from HES was accurate when compared
to data collected from medical notes review.3 The mean differ-
ence in costs between the two methods was £899 with HES
calculating 8% lower costs than medical records. HES data
could, therefore, be useful in trials aiming to analyse the eco-
nomic impact of treatments. Traditional trial follow-up pre-spe-
ciﬁes the deﬁnitions of a clinical event using thresholds for
conﬁrming a diagnosis. This selective approach may not accur-
ately reﬂect the patient experience or cost to the health service.
A recent study looked at the non-fatal/non-MACE adverse
events in a trial comparing percutaneous coronary intervention
(PCI) to coronary artery bypass graft (CABG) in patients with
2 or 3-vessel coronary artery disease.4 The results showed that
CABG was associated with a greater number of non-MACE
events despite the original trial publication favouring CABG
because of a lower number of MACE adverse events.5 MACE
are commonly used as the primary outcome measures in trials
of cardiovascular interventions. Since HES identiﬁes any hos-
pital admission, these data could be used in trials wishing to
examine the broader physical and psychological impact of
admission.
The accuracy of HES data may vary over time between
institutions and is dependent on the quality of the clinical
coding performed by each NHS trust. In 2013-14 an audit
was performed of the clinical coding at 50 acute trusts asses-
sing the accuracy of the ICD-10 codes allocated to each
admission. The average error rate, deﬁned as a change to
the codes that would results in a change in the payment
received by each trust, was 7%.6 The lowest percentage error
for a given trust was 1.1% and the highest 45.8%, demon-
strating considerable variability in the accuracy of clinical
coding across trusts. A systematic review performed in 2013
looked at studies of the accuracy of HES data when com-
pared to clinical registries and case notes.7 Although there is
no consensus for an acceptable threshold of diagnostic
accuracy, the median accuracy of the HES diagnostic codes
was 80.3% when compared to notes review or clinical regis-
try data.8 This review also found that there has been an
improvement in the diagnostic accuracy of HES data over
time. A recent study by Wright-Hughes et al.,9 assessing the
accuracy of HES data in a trial investigating self-harm in
adolescents found that HES identiﬁed more than double the
Table 2 The diagnostic accuracy of the HES data in identifying patients with outcome events during the index admission and in any readmission in the
follow-up period is compared to the standard provided by the adjudicated events. By assuming the adjudicated events are accurate, the sensitivity and
speciﬁcity of each method can be calculated
Outcome from Physician
Adjudication
Sensitivity (CI) Speciﬁcity (CI) PPV (CI) NPV (CI)
No. of patients with event before discharge Recurrent MI No recurrent MI
HES detects recurrent MI 1 15
HES does not detect recurrent MI 28 1710 3.4 (0.6–17.2) 99.1 (98.6–99.5) 6.2 (1.1–28.3) 98.3 (97.7–98.9)
CVA No CVA
HES detects CVA 16 1
HES does not detect CVA 6 1731 72.7 (51.8–86.8) 99.9 (99.7–99.9) 94.1 (73.0–98.9) 99.7 (99.2–99.8)
Bleed No bleed
HES detects bleeding 143 175
HES does not detect bleeding 79 1357 64.6 (57.9–70.4) 88.6 (86.7–90.0) 44.9 (39.6–50.5) 94.4 (93.2–95.6)
No. of patients with events after discharge
Recurrent MI No recurrent MI
HES detects recurrent MI 2 46
HES does not detect recurrent MI 1 1705 66.7 (20.8–93.9) 97.4 (96.5–98.0) 4.2 (1.2–13.9) 99.9 (99.7–100)
CVA No CVA
HES detects CVA 4 8
HES does not detect CVA 1 1741 80.0 (37.6–96.4) 99.5 (99.1–99.8) 33.3 (13.8–60.9) 99.9 (99.7–100)
Bleed No bleeding
HES detects bleeding 15 7
HES does not detect bleeding 16 1716 48.4 (32.0–65.2) 99.6 (99.2–99.8) 68.2 (47.3–83.6) 99.1 (98.5–99.4)
HES = Hospital Episode Statistics; DC = direct contact; CI = 95% conﬁdence interval; PPV = positive predictive value; NPV = negative predictive value;
CVA = cerebrovascular accident; MI = myocardial infarction.
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number of hospital attendances that were recorded by
researchers. In addition, HES identiﬁed only 62% of self-
harm diagnoses reported by researchers. This study con-
cluded that HES data are useful in identifying hospital
admissions but less accurate in identifying trial-speciﬁc clin-
ical diagnoses.
What this study adds
In our study, 153/153 = 100% of the readmissions identi-
ﬁed by HES were conﬁrmed by medical notes review. In
comparison, 66/210 = 31.4% of readmissions were identi-
ﬁed incorrectly by DC. Using HES data remove the need to
directly contact any trial patient and is likely to reduce the
workload of a trial and subsequently the overall cost. When
a patient reports a clinical event or readmission, this is thor-
oughly investigated by the research team, who must review
the medical notes to conﬁrm or refute the claim. If HES
data are used, the reduction in workload may allow trial cen-
tres to divert resources from follow-up to trial recruitment
activity.
This study showed that accuracy of HES in identifying
clinical events is limited, in terms of the speciﬁc diagnostic
thresholds that are the norm in clinical trials. The highly spe-
ciﬁc trial deﬁnitions of clinical outcomes in the HEAT-PPCI
trial were not developed to be comparable to the ICD-10
codes used in HES. Therefore, the frequency of clinical
events identiﬁed in HES is likely to differ when compared
to physician adjudicated events. For instance, we were
unable to stratify bleeding events into degrees of severity
because this is not speciﬁed in any ICD-10 code. Therefore,
regardless of severity, all bleeds were ﬂagged as events. This
demonstrates the limitations related to the number and com-
plexity of diagnoses included in the ICD-10. For researchers
planning to use HES in a clinical trial, one solution would
be to tailor clinical outcomes to speciﬁc ICD-10 diagnoses.
This would ensure that the pre-speciﬁed outcome measure
can be identiﬁed in the HES database.
We were unable to perform analyses for the outcomes of
unplanned target lesion revascularisation because we could
not apply the usual range of trial qualiﬁers to the outcome
of additional revascularisation. For example, the ICD-10
codes do not distinguish between planned and unplanned
revascularisation. A possible solution would be to ensure
future treatment intentions are recorded on the clinical
record form of each patient following the index event. This
information could then be used with the HES database to
establish if further intervention was planned or unplanned.
HES data only reports admissions that occur in hospitals
in England. Of the 14 false negative readmission events, 2
occurred outside this area. This limits the usefulness of HES
data in tracking patients who move outside of England, or
those who are admitted to hospitals when abroad. One solu-
tion would be to limit study inclusion to those with NHS
numbers who are resident in England. However, this limits
the recruitment and ability to generalize the results of the
study and does not solve the issue of patients who are
admitted to hospitals abroad or who live on the border of
England and another UK home nation or the Republic of
Ireland. There is an equivalent of HES data for Wales and
Scotland, which also use ICD-10 codes and should be used
in addition to the English HES database.
The use of the NHS number as an identiﬁer is useful in
trials with lengthy follow-up because the NHS number
remains the same even if a patient moves or changes their
name or phone number. However, patients without an NHS
number will be missed. In this study, 58/1812 = 3.2% of
patients did not return any data in the HES database. There
were 13/58 = 22.4% patients who did not have an NHS
number and an error was found in the NHS number of 2/
58 = 3.4%, so the HES database could not identify these
patients. This error could be reduced by using a simple
check digit code to ensure all NHS numbers are correct at
the time of original recruitment. Using more meticulous
methods of checking and rechecking the NHS number by
the study team would also reduce errors.
Limitations of this study
This study reported very small numbers of clinical events
prompting readmission following the index event. For
example, only ﬁve strokes occurred after the index admis-
sion. It is therefore impossible to draw conclusions from
such numbers. This study assessed identiﬁcation of recur-
rent MI, CVAs and bleeding events. Our assessment of the
diagnostic accuracy of HES data is therefore limited to a
small number of ICD-10 codes. This limits the generalizabil-
ity of our results to studies looking at similar outcome mea-
sures. More studies should be performed to assess the
accuracy of HES data across a wider range of diagnostic
codes.
Data from medical notes and physician adjudication were
used to conﬁrm the occurrence of a readmission or clinical
event. We, therefore, had to assume that the medical notes
are accurate and complete. Any errors or omissions in the
medical notes would have affected our results.
The adjudication seeks to ensure events are declared to
match trial deﬁnitions. These may be different from ‘normal’
clinical deﬁnitions and from the deﬁnitions used to code
diagnoses in HES. Therefore, when using the same clinical
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information, there may be differences in the numbers of
outcomes reported by each, creating perceived errors in the
HES data.
Suspected readmissions identiﬁed by DC and HES were
subsequently conﬁrmed or refuted by medical notes review.
For conﬁrmation to occur, the suspected readmission had to
be initially identiﬁed by either DC or HES. Therefore, any
readmissions missed by both DC and HES would not have
been identiﬁed in the HEAT-PPCI trial follow-up. To ensure
all readmission events were identiﬁed, without using DC or
HES, the medical notes of every patient in the HEAT-PPCI
trial would have to be reviewed which was beyond the
resources of this study.
Conclusion
A combination of HES and direct contact provides a com-
prehensive method of follow-up superior to either method
alone. Using HES may reduce the resource burden and cost
of follow-up in clinical studies. HES cannot accurately iden-
tify outcome measure events to match speciﬁc trial deﬁni-
tions tested by independent adjudication. However, the
numbers of clinical events in this analysis are too small to
draw deﬁnite conclusions about the accuracy of HES data
when used for this purpose. A HES-based approach may
also provide information about the general patient experi-
ence and total healthcare costs of a trial. Using HES may
support patient recruitment and the completeness of follow-
up by reducing the workload for both investigators and
patients.
Supplementary data
Supplementary data are available at the Journal of Public
Health online.
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